Shionogi to Absorb Torii Pharmaceutical in 2027 to Boost Domestic Pharma Synergies

Shionogi & Co ( (JP:4507) ) has provided an announcement.

Shionogi & Co., Ltd. has set a basic policy to carry out an absorption-type merger of its wholly owned subsidiary Torii Pharmaceutical Co., Ltd., with Shionogi as the surviving entity, effective April 1, 2027. The move follows Shionogi’s 2025 tender offer that led to Torii’s full ownership and aims to deepen integration, accelerate unified decision-making, and maximize synergies, particularly in allergy and dermatology, to expand patient reach and reinforce the stability of its domestic pharmaceutical operations.

Under the planned structure, Torii Pharmaceutical, which specializes in the manufacture and sale of pharmaceutical products, will be absorbed without issuing new shares or providing other consideration, as it is already fully owned by Shionogi. By consolidating Torii’s expertise in areas with significant unmet medical needs and relatively stable demand, Shionogi expects to enhance its ability to deliver core products, strengthen medical information and promotional activities, and bolster its long-term competitive position in the Japanese pharmaceutical market.

The most recent analyst rating on (JP:4507) stock is a Buy with a Yen4031.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.

More about Shionogi & Co

Shionogi & Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription medicines. The group focuses on strengthening its domestic business by leveraging expertise across therapeutic areas, including allergy and skin diseases, to build a stable and sustainable healthcare-focused revenue base.

Average Trading Volume: 2,983,940

Technical Sentiment Signal: Buy

Current Market Cap: Yen3144.3B

Learn more about 4507 stock on TipRanks’ Stock Analysis page.